Noticias y Actividades de SurModics
Presencia
SurModics es una de las ...
SurModics es una empresa que cotiza bajo el símbolo de cotización SRDX (US).
Fusión, adquisición y financiación con participación de SurModics.
- GTCR has announced the acquisition of SurModics (publicado el 3 de junio de 2024).
Ejecutivos
Ver el organigrama con sus 31 ejecutivos principales
Biografías más buscadas en SurModics
- Gary Maharaj, President and Chief Executive Officer, Director
- Jose Bedoya, Director
- Lisa Heine, Director
Recientes movimientos de ejecutivos en SurModics
- Tom Worthington, National Sales Director, ha dejado la empresa (noticia publicada el 5 de noviembre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en SurModics.
Química
SurModics tiene 1.014 competidores entre los que se incluyen BASF (Alemania), Air Liquide (Francia) y AkzoNobel (Países Bajos).
Popular M&A news in Química
- Granules India ha Senn Chemicals adquirido (publicado el 14 de abril de 2025).
- Pritzker Private Capital has announced the acquisition of Americhem (publicado el 24 de febrero de 2025).
- Piedmont Lithium and Sayona Mining have announced they will merge (publicado el 19 de noviembre de 2024)..
Otros contactos sugeridos en el sector Química
Noticias
Últimos comunicados de prensa de SurModics
- Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries | Surmodics, Inc.
- Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR | Surmodics, Inc.
- Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results | Surmodics, Inc.
- Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries | Surmodics, Inc.
- News Releases | Surmodics, Inc.
- Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Surmodics, Inc.
- Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System | Surmodics, Inc.
- Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter | Surmodics, Inc.
- Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results | Surmodics, Inc.
- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. | Surmodics, Inc.
- View more press releases Close
Redes sociales sobre SurModics
- SurModics en Wikipedia, Google News y Yahoo Finance
- SurModics en LinkedIn, Twitter y YouTube
